Research Objective To report 3-year results of the tube versus trabeculectomy (TVT) study. Study Design Multicenter randomized clinical trial. Location Seventeen clinical centers in the United States. Funding Source Pfizer Inc, New York, NY; Advanced Medical Optics, Irvine, CA; the National Eye Institute, National Institutes of Health, Bethesda, MD; and Research to Prevent Blindness Inc, New York, NY. Relevant Methodology The study cohort consisted of 212 eyes of 212 patients (107 in the tube group and 105 in the trabeculectomy group) aged 18 to 85 years and who had earlier trabeculectomy, cataract extraction with intraocular lens implantation, or both and uncontrolled glaucoma with intraocular pressure (IOP) > 18 mm Hg and <40mm Hg on maximum tolerated medical therapy. They received either a 350-mm~2 Baerveldt glaucoma implant or trabeculectomy with mitomycin C (MMC: 0.4 mg/mL for 4 min).
展开▼
机译：研究目的报告3个月的小管切除术与小梁切除术（TVT）研究的结果。研究设计多中心随机临床试验。地点在美国有17个临床中心。资金来源辉瑞公司，纽约，纽约;加州尔湾市高级医学光学;美国马里兰州贝塞斯达市国立卫生研究院国家眼科研究所;和纽约州纽约市防止盲症研究公司。相关方法该研究队列包括年龄在18至85岁之间的212例患者（212眼，小管组107例，小梁切除术组105例）的212眼，这些患者较早进行了小梁切除术，白内障摘除联合人工晶状体植入术，或两者并用，而无控制性青光眼合并人工晶状体最大耐受药物治疗的最大压力（IOP）> 18 mm Hg和<40mm Hg。他们接受了350mm〜2 Baerveldt青光眼植入物或丝裂霉素C小梁切除术（MMC：0.4 mg / mL，持续4分钟）。
展开▼
